Open Access Open Badges Research

Niemann-Pick disease type C clinical database: cognitive and coordination deficits are early disease indicators

Miriam Stampfer1, Susanne Theiss1, Yasmina Amraoui2, Xuntian Jiang3, Sigrid Keller2, Daniel S Ory3, Eugen Mengel2, Christine Fischer1 and Heiko Runz14*

Author Affiliations

1 Institute of Human Genetics, University of Heidelberg, INF 366, Heidelberg 69120, Germany

2 Center for Pediatric and Adolescent Medicine, University of Mainz, Mainz, Germany

3 Diabetic Cardiovascular Disease Center, Washington University School of Medicine, St. Louis, MO, USA

4 Molecular Medicine Partnership Unit (MMPU), University of Heidelberg/EMBL, Heidelberg, Germany

For all author emails, please log on.

Orphanet Journal of Rare Diseases 2013, 8:35  doi:10.1186/1750-1172-8-35

Published: 22 February 2013



The neurodegenerative lysosomal storage disorder Niemann-Pick disease type C (NP-C) is characterized by a broad clinical variability involving neurological, psychiatric and systemic signs. Diverse patterns of disease manifestation and progression considerably delay its diagnosis. Here we introduce the NP-C clinical database (NPC-cdb) to systematically obtain, store and analyze diagnostic and clinical findings in patients with NP-C. We apply NPC-cdb to study NP-C temporal expression in a large German-Swiss patient cohort.


Current and past medical history was systematically acquired from 42 patients using tailored questionnaires. Manifestation of 72 distinct neuropsychiatric signs was modeled over the course of disease. The sequence of disease progression was re-constructed by a novel clinical outcome scale (NPC-cdb score).


The efficiency of current clinical diagnostic standards negatively correlates with duration of disease (p<3.9x10-4), suggesting insufficient sensitivity in patients early in the disease process. Neurological signs considered as typical for NP-C were frequent (e.g., cognitive impairment 86%, ataxia 79%, vertical supranuclear gaze palsy 76%) and their presence co-occurred with accelerated diagnosis. However, less specific neuropsychiatric signs were reported to arise considerably more early in the disease process (e.g., clumsiness -4.9±1.1 y before diagnosis). Most patients showed a steady disease progression that correlated with age at neurological onset. However, a distinct subcohort (n=6) with initially steadily progressing disease later showed a 2.9-fold accelerated progression that was associated with the onset of seizures (p<7x10-4), suggesting seizures as predictive for a poor prognosis.


Considering early, but less specific neuropsychiatric signs may accelerate the path to diagnosing NP-C in a patient.

Cholesterol; Clinical repository; Genotype-phenotype; Neurodegenerative disease; Oxysterols